Oxurion NV (OXUR)
XBRU 
Summary
OXUR Chart
People also search for
Oxurion NV (OXUR) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Oxurion NV ever had a stock split?
Oxurion NV Profile
| Biotechnology Industry | Healthcare Sector | Mr. Pascal Ghoson CEO | XBRU Exchange | BE0003846632 ISIN |
| BE Country | 11 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Oxurion NV, initially established as ThromboGenics NV in 1991, is a pioneering biopharmaceutical firm based in Leuven, Belgium, with a global operational reach. In September 2018, the company embraced its current identity, Oxurion NV, signifying a strategic evolution in its mission. Oxurion is dedicated to the development and commercialization of innovative treatments targeting eye diseases, leveraging cutting-edge scientific research to improve patient outcomes. Its activities encompass a collaborative ethos, partnering with entities like Bicycle Therapeutics and Galapagos NV to bolster its development pipeline and expand its therapeutic horizons.
Products and Services
JETREA:
As Oxurion NV’s flagship product, JETREA represents a significant advance in the treatment of vitreomacular adhesion/vitreomacular traction. This injectable treatment, grounded in the company's expertise in ophthalmology, offers patients suffering from these conditions a potentially sight-saving option, mitigating the progression towards severe vision loss.
THR-149:
In the pipeline is THR-149, a promising plasma kallikrein inhibitor currently in Phase II clinical trials. Specially formulated to address diabetic macular edema (DME), THR-149 aims to provide a new therapeutic mechanism targeting the underlying processes that exacerbate this condition, which is a leading cause of blindness among adults.
THR-687:
Also in development for the treatment of diabetic macular edema is THR-687, an integrin antagonist. Currently progressing through Phase II clinical trials, THR-687 is designed to counteract the vascular and inflammatory processes that contribute to DME. By blocking specific pathways associated with the disease’s progression, THR-687 demonstrates Oxurion's commitment to offering diverse and innovative treatment options for DME patients.
